RedHill Biopharma Ltd (RDHL)

[midastouch017]

RedHill Biopharma highlights presentation of oral opaganib phase 2 data in COVID-19

Jun. 21, 2021 8:50 AM ETRedHill Biopharma Ltd. (RDHL)

By: Aakash Babu, SA News Editor

RedHill Biopharma (NASDAQ:RDHL) announces the presentation of positive Phase 2 safety and efficacy data for oral opaganib in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021.

Shares up marginally during premarket trading.

Data showed that, 86.4% of patients treated with opaganib were discharged from hospital by Day 14 compared to 55.6% of patients treated with placebo. Median time to discharge was 6 days for the opaganib group compared to 7.5 days for the placebo group

81.8% of opaganib patients achieved a 2-point improvement in the WHO Ordinal Scale compared to 55.6% of patients in the placebo group.

No significant differences in safety-related measures between the two groups.

RedHill had completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib in patients hospitalized with severe COVID-19 pneumonia, earlier this month.